Navigation Links
Pharsight Uses FDA Disease Model to Support Oncology Drug Development
Date:11/20/2007

Use of FDA Model in Non-Small Cell Lung Cancer Expected to Inform

Quantitative Predictions for Experimental Cancer Treatment

MOUNTAIN VIEW, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHRS), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that its Strategic Consulting Services Group is using a quantitative disease model developed by the Food and Drug Administration (FDA) for non-small cell lung cancer (NSCLC) to support an oncology drug development program sponsored by one of its clients, a global pharmaceutical company.

Pharsight scientists are using FDA's publicly available model in NSCLC to perform simulations of expected survival based on tumor shrinkage for an investigational drug in early clinical studies. Pharsight scientists also expect to refine these simulations with emerging data in new clinical studies to assist with key oncology development program decisions, including optimized dose selection and improved design of survival trials.

Pharsight's collective modeling and simulation experience in oncology includes longitudinal exposure-response modeling to inform labeling decisions and test dosing strategies, allometric projections, and work with novel mechanisms.

FDA has developed several quantitative drug-disease models based on the literature and clinical trial data from sponsor submissions for drug approval. FDA does not release proprietary source data from sponsors used to develop and validate the models, but the agency has underscored its commitment to publicly sharing and further testing the models that it has developed in important disease areas, including oncology. The NSCLC model was presented by FDA scientists at a January 2007 meeting, co-sponsored by FDA and the Drug Information Association (DIA), entitled "Sharing Knowledge to Improve Clinical Drug Development and Regulator
'/>"/>

SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
9. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
10. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
11. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...swire/ -- New research has found that the availabi... (CT) scanner in an emergency room can significant...ve a potentially life-saving treatment. Results of...r (NSMC)-Salem Hospital in Salem, Mass., will be p...ogical Society of North America (RSNA). , , ...
(Date:12/1/2008)... A study has found that...que for imaging the breast, is not affected by eit...wo factors that limit the effectiveness of standar... will be presented today at the annual meeting of ... , , "The ability of PEM to detect cancer d...
(Date:12/1/2008)...e-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq...e of the world,s leading medical journals, results...or, experimental compound tasimelteon (VEC-162). ... "Melatonin agonist tasimelteon (VEC-162) for tran...sed controlled multicentre trials." Results are re...
(Date:12/1/2008)... TargeGen has announced that an oral,presentation...ased clinical,trial of TG101348 in myeloprolifera...008 American Society of Hematology (ASH) Meeting. ...ows:, Title: A Phase I Study of... JAK2-Selective Inhibitor, in Patients wit...
Breaking Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Governors Task Force Cites PAs 2436 5 Billion Water Infrastructure Need 3B Report Underscores Call for Additional Investments 28454 1Governors Task Force Cites PAs 2436 5 Billion Water Infrastructure Need 3B Report Underscores Call for Additional Investments 28454 2Governors Task Force Cites PAs 2436 5 Billion Water Infrastructure Need 3B Report Underscores Call for Additional Investments 28454 3Turning Clocks Back Increases Risk of Drowsy Driving 28449 1Turning Clocks Back Increases Risk of Drowsy Driving 28449 2Nutrition 21 to Report Preliminary First Quarter Fiscal Year 2009 Financial Results on Thursday November 13 2008 28446 1Nutrition 21 to Report Preliminary First Quarter Fiscal Year 2009 Financial Results on Thursday November 13 2008 28446 2FDA Warns of Dangers of Mexican Vanilla 28441 1
...hase 2 BPD Clinical Data Selected and Presented as...lis Aerosol-Generator Technology,Demonstrates Opti...2007 (PRIME NEWSWIRE) -- Discovery,Laboratories, I...previously completed Phase 2 clinical trial of Sur...r the prevention and,treatment of Bronchopulmonary...
...ieves Primary Endpoint Among High-Risk Infants Ver...f Medically Attended,Outpatient RSV- Related Lower...PRNewswire-FirstCall/ -- MedImmune, Inc.,today ann...rial,conducted for prevention of respiratory syncy...the investigational monoclonal antibody,(MAb) also...
Other Medicine Technology:Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 2Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 3Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 4Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 5Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 6Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 7MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 2MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 3MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 4MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 5MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 6MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 7
(Date:12/2/2008)... Dec. 2 Population Serv...hensive project that could dramatically reduce the...malaria. The program will provide free artemisinin...community health workers to poor children suspecte...to treatment will be monitored to determine if it ...
(Date:12/1/2008)... CHICAGO, Dec. 2 Includ...y enable a more meticulous reading from the radiol...ersonal and empathetic approach, according to a st...adiological Society of North America (RSNA). , ...nt as a human being and not as an anonymous case s...
(Date:12/1/2008)... Ind., Dec. 2 Patient satisfaction...on the rise according to a new report,from Press ...Report: Patient,Perspectives on American Health C...as a driver for improvement in patient services. ...llion patients treated at more than,1,200 outpati...
(Date:12/1/2008)...c. 2 New research revea...o known as virtual colonoscopy, has the potential ...cer and osteoporosis, both of which commonly affec... presented today at the annual meeting of the Radi..., "With CT colonography, in addition to screenin...
Breaking Medicine News(10 mins):Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Patient Photos Spur Radiologist Empathy and Eye for Detail 2Health News:Patient Photos Spur Radiologist Empathy and Eye for Detail 3Health News:Outpatient Service Facilities Face Increasing Competition - Patient Perceptions More Important Than Ever 2Health News:CT Colonography Offers One-Stop Screening for Cancer and Osteoporosis 2Health News:CT Colonography Offers One-Stop Screening for Cancer and Osteoporosis 3
... have found out that Methicillin-resistant Staphyl...e// who before had no established risk factors for...RSA infections, and reviewing their medical record...these infections are acquired from the community. ...
...y on child behavior had pointed out that excessive... might make the child indulge in bullying behavior...peatedly harasses and attacks other children. Bull...physical attack on others or by verbal assaults, t...
...s at Institute of Bioinformatics (Bangalore) had m...omosome// with its transcriptome and proteome sequ...uman X chromosome has a gene density less than oth...oding regions and 696 known genes. The researcher...
...was conducted to find out effective treatment for ...both knees. // The treatment tested was providing...and one third patch on the back of the affected kn...ix weeks of treatment majority of the group of peo...
Other Medicine News:
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine specimens
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
Medicine Products: